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TOLNAFTATE THERAPY OF MYCOTIC INFECTIONS
PRELIMINARY REPORT*
HARRY M. ROBINSON, JR., M.D. AND JOAN RASKI N, M.D.
Prior to the introduction of the systemic use of
griseofulvin for the treatment of selected super-
ficial mycotic infections, there was no satisfactory
method of management available. Although great
claims had been made for some of the topical
proprietary preparations, at best they were proved
to be only palliative, the main virtue being the
keratolytic effect produced by them. In spite of
the fact that there is a low incidence of adverse
reactions to griseofulvin, the problems of photo-
sensitivity, gastrointestinal disturbances, head-
ache, etc. are still encountered. Topically applied
griseofulvin, regardless of the excipient used, is of
questionable value. It is evident that an efficient
topical fungicidal or fungistatic agent with a low
incidence of sensitivity reaction would be of in-
estimable therapeutic value.
During the past ten years, Japanese scientists
(1) have assayed more than 3000 topically applied
compounds for toxicity and antifungal activity.
In 1960 a group of agents with antifungal prop-
erties was derived from 0-2-naphthyl-N-inethyl-
thionocarbamates. The most promising compound
of this group proved to be 0-2-Naphthyl m, N-di-
inethylthiocarbanilate.
This drug, in two dilutions, one of its congeners,
and a control were submitted under blind label for
clinical and laboratory investigation. This report
contains the results of the preliminary study.
METnons AND MATERIALS
The drugs: Supplies of four different prepara-
tions, in identical plastic containers, labelled A.
B, C, and D were delivered for study. The code
was contained in a sealed envelope which was not
opened until a sufficient number of patients had
been treated to allow conclusions to be drawn.
The plastic squeeze bottles had narrow openings
to permit drop control of the medication. The
control used was polyethylene glycol 400, the
solvent used for the active agents. Each of the
preparations and the control were identical in
appearance and consistency.
The major portion of this study was performed
with tolnaftate (0-2-Naphthyl m, N-dimethyl-
thiocarbanilate) using dilutions of 1.0% and
0.5%. A congener, 0-2-naphthyl-N-methyl-1 -
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naphthylthiocarbamate, was used in the treatment
of 23 patients but study with this compound was
discontinued because it proved to be only fungi-
static whereas tolnaftate is fungicidal. These com-
pounds are soluble in organic solvents but are
virtually insoluble in water. The preparations as
dispensed were odorless and colorless.
The toxicity to man on topical application or on
oral administration is virtually negligible (1).
Tolnaftate proved to be totally ineffective on oral
and parenteral administration. In laboratory ani-
mals the drug was found to have no pharmacologic
action on the cardiovascular apparatus, the
central nervous system, or the respiratory ap-
paratus. The results of these studies by Japanese
investigators (1) have been confirmed in the
United States by similar experiments (2). If per-
cutaneous absorption of tolnaftate does occur,
the possibility of organic damage is negligible.
Patient selection: Those included in this study
were diagnosed and treated in the out-patient
dermatology clinic of the University of Maryland
and the authors' private practice. The range in
age was from 9 to 70 years. White and Negro pa-
tients of both sexes were included.
Treatment was initiated in 96 patients but of
this number, seventy five completed the prescribed
course. Direct microscopic examinations were
positive for hyphae in all patients before medica-
tions were prescribed. Cultures on Sabouraud's
medium were obtained from all of them at the
time of the initial visit, except the six who had
tinea versicolor. Culture results from the other
sixty-nine patients who completed treatment were
as follows:
Trichophyton rubruin 49
Candida albicans 3
Epidermophyton floccosuni 2
Trichophyton mentagrophytes 2
Microsporum audnuini 1
Conta,ninated cultures (organism not 12
identified)
The twelve patients from whom the twelve
contaminated cultures were obtained had clinical
lesions of tinea corporis on the trunk.
Both local and disseminated lesions were pres-
ent in the patients included in this series. The
distribution of lesions and diagnoses were as
shown in Table 1.
Procedure: After the diagnosis of a mycotic in-
faction was established by direct microscopic cx-
amination, a culture was made and the selected
medication furnished to the patient with instruc-
tions to apply a thin fibn twice daily to the in-
volved areas with a gentle rubbing motion. Solu-
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TABLE 1
Number
of Location of Lesions Coltore
Patients
14 groins Trichophyton rubrum
2 Candida albicans
4 Contaminated culture
4 one or both
hands
Trichophyton rubrum
10 one or both Trichophyton rubrum
3 feet Contaminated culture
2 Trichophyton menta-
grophytes
1 Candida albicans
1 Epidermophyton
fioccosum
11 body or extre- Trichophyton rubrum
1 mities Epidermophyton
floccosum
2 Contaminated culture
4 toenails or
fingernails
Trichophyton rubrum
1 scalp Microsporum audouini
5 bands and feet Trichophyton rubrum
1 Contaminated culture
1 groins and Triehophyton rubrum
2 feet Contaminated culture
6 tinea versi-
color on
body
No culture
tion "C", found by clinical trial to be the non-
medicated placebo, was given to five patients.
When no improvement was noted with solution
"C" after one week, solution "B" or "D" was
administered. Solution "A", later proved to
be the fungistatic congener and subsequently
dropped from the study, was prescribed for 23
patients. Three patients in this latter group had
recurrence of lesions and were subsequently
treated with the "D" solution (0.5% tolnaftate).
This solution was also given to 23 additional pa-
tients. The "B" solution (1.0% tolnaftate) was
used in the treatment of 29 patients. Post-treat-
ment direct microscopic examinations were per-
formed on the 6 patients who had tinea versicolor.
Post-treatment cultures were made from the site
of prior involvement of the other patients with
superficial mycotie infections.
REsULTs
Control stndy: Five patients with Trichophyton
rubrum infections of the groins were treated with
the non-medicated placebo for one week. No re-
lief of subjective symptoms or change in the ap-
pearance of the cutaneous lesions was observed
following the use of this preparation (solution
"C''). Preparation ''B'' (1% tolnaftate solution)
was used in the treatment of 3 of these patients
and preparation "D" (0.5% tolnaftate solution)
was administered to the other two. Relief of sub-jective symptoms occurred in all 5 patients in
from 24 to 72 hours and involution of lesions was
complete in from 2 to 3 weeks. The "B" and "D"
solutions produced identical results.
Tinea versicolor: Four of these patients were
treated with "B" solution and 2 with the "D"
solution. After a period of 2 to 3 weeks, there was
partial to complete disappearance of scale from
the lesions but in all instances, in spite of clinical
improvement, direct microscopic examination was
positive for Malessezia forfur.
Moniliel infections: One patient with candida
albieans infection between the toes was treated
with solution "A" (the congener) and 2 patients
with candida albicans infections of the groins
were treated with solution "B" (1% tolnaftate
solution). There was no evidence of clinical im-
provement in any of these 3 patients after 2 weeks
of treatment.
Trichophyton rubrum infections: Sixteen pa-
tients with Trichophyton rubrum infections were
treated with solution "A" (the congener). Six of
these had interdigital involvement of the feet,
two had lesions on the trunk, three had tinea
cruris and two involvement of the toenails. In
four other patients who had lesions clinically
characteristic of Trichophyton rnbrum infections,
the initial culture was contaminated although the
direct microscopic examinations were positive.
These patients were also treated with solution
"A". After one month of treatment no appreciable
change was observed in the toenail lesions and
therefore treatment was discontinued. Relief from
itching occurred in from 24 to 72 hours in all of
the other patients. The interdigital lesions showed
improvement in one week and in all instances dis-
appeared in 2 to 3 weeks. Lesions on the trunk,
groin and extremities showed marked improve-
ment during the first week of treatment and
complete clearing in from 2 to 4 weeks. There was
clinical relapse of groin and trunk lesions in 3
patients who subsequently responded to treat-
ment with solution "D". No evidence of irritation
or hypersensitivity developed from the use of this
solution.
Solution "B" (1% tolnaftate) was used in the
treatment of 16 patients with Trichophyton robrunt
infections. Six additional patients whose initial
culture was contaminated but who had clinical
lesions characteristic of Trichophyton rubrum in-
fections were also treated with solution "B". Re-
lief from itching was prompt in from 24 to 72 hours
in all cases. All patients in this group showed some
degree of improvement within 7 days and in all
instances involution of lesions was complete in
from 2 to 4 weeks. After one month of treatment,
no improvement was observed in the single ease
of onyehomyeosis and because of this treatment
was discontinued. No evidence of irritation or
hypersensitivity developed from the use of this
solution.
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Solution "D" (0.5% tolnaftate) was used in
the treatment of 17 patients who had positive
cultures for trichophyton rubrum aud in 2 other
patients who had lesions clinically characteristic
of Trichophyton rubrum infections but whose
initial cultures were contaminated. Significant
improvement was not observed in the one patient
who had onychomycosis and therefore treatment
was discontinued. In all of the other patients there
was prompt relief from itching in from 24 to 72
hours. Clinical improvement was observed at the
end of one week in all instances and complete in-
volution of lesions was observed in 2 to 4 weeks.
No evidence of irritation or hypersensitivity was
noted. Positive cultures were obtained from 3
of these patients after all clinical evidence of in-
fection had disappeared.
Epidermophyton fioccosum: Two patients with
Epidermophyton floccosum of the feet and trunk
were studied. One of these was treated with solu-
tion "D" (0.5% tolnaftate) and the other with
solution "B" (1.0% tolnaftate). In both iustances
there was relief from itching in from 24 to 72 hours.
Partial involution of lesions occurred in one week
and in both instances complete involution of
lesions had occurred in 3 weeks. No evidence of
irritation or hypersensitivity occurred from the
medication.
Trichophyton mentegrophytes infections: Two
patients with tinea pedis due to this organism
were treated with solution "A". Relief from itch-
ing occurred in from 24 to 72 hours and in both
instances involution of lesions was complete
within 3 weeks.
COMMENT
This preliminary study indicates that tolnaf-
tate, topically applied, is an effective agent for
the treatment of superficial myeotic infections
due to Trichophyton rubrum, Epidermophyton
floccosum and Trichophyton menteyrophytes. The
observations recorded reveal no incidence of
primary irritation or acquired contact sensitivity.
Although the experience is slight, tolnaftate is
apparently of no value in the treatment of tinea
capitis, or cutaneous lesions due to Candida
elbicens. It is difficult to evaluate this drug in
the management of onychomycosis because of the
prolonged observation time necessary. During the
time of this study, satisfactory improvement was
not observed in the nail infections of the four pa-
tients treated with topical applications of tolnaf-
tate. Rapid and complete clearing of interdigital
fungus infections was noted in all cases treated.
In these eases, tolnaftate produced involution of
lesions, a result which could not be obtained with
systemically administered griseofulvin or kera-
tolytie agents such as undecylenie acid or salicylie
acid. In all instances in which itching was a prom-
inent symptom, relief of subjective symptoms oc-
curred in 24 to 72 hours.
This initial report indicates that tolnaftate is a
valuable and effective fungieidal agent with a low
index of sensitization. Obviously a more extensive
study must be done with a larger series of patients.
It would be desirable to include in future studies
eruptions due to as many of the dermatophytes as
possible. Further in vitro studies are indicated to
determine the spectrum of tolnaftate and its mode
of action.
CONCLUSIONS
1. Tolnaftate (0.5% and 1.0% in polyethylene
glycol 400) is an effeetive agent in the treatment
of superficial mycotic infections due to Tricho-
phyton rubrum, Trichophyton menteyrophytes, and
Epidermophyton fioccosum, and produces rapid
clearing of interdigital infections due to these
fungi.
2. This drug is of no value in the treatment of
Candida elbicens infections, in the management
of tinea eapitis, and of questionable value in tinea
versicolor.
3. More intensive study and different technic
are required to determine its value in onyehomy-
cosis. Satisfactory results were not obtained in
the present study.
4. No evidence of primary irritation or hyper-
sensitivity was observed.
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